Merkel cell carcinoma in immunosuppressed patients
Related Experiment Video
Updated: Apr 27, 2026
Merkel Cell Polyomavirus Infection and Detection
Published on: February 7, 2019
1Mayo Clinic College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. ma.janice@mayo.edu.
Abstract:
Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous malignancy. The infectivity of Merkel cell polyomavirus (MCPyV), an apparent agent in MCC development, may be exacerbated with impaired immune responses. This paper reviews relevant data regarding the role of immunosuppression in the development of MCC and describes modes of immunodeficient states. Because of the inherently low incidence rate of MCC, several case studies and series are also briefly mentioned to provide a more comprehensive summary of MCC in the setting of immunosuppression. We describe immunosuppressed patients who have experienced excessive UV radiation, organ transplantation, human immunodeficiency virus infection/AIDS, autoimmune diseases, and lymphoproliferative disorders. Iatrogenic forms of immunosuppression are also highlighted. Studies that quantify risks consistently report that individuals with a history of solid organ transplantation, autoimmune diseases, AIDS, and/or lymphoproliferative diseases have a significantly elevated risk of developing MCC. Overall, immunocompromised patients also appear to have an early onset and more aggressive course of MCC, with poorer outcomes. Recommendations for multidisciplinary approaches are proposed to effectively prevent and manage MCC in these patients.
Insights
Merkel cell carcinoma (MCC), a rare skin cancer, is linked to Merkel cell polyomavirus (MCPyV). Immunosuppression significantly elevates MCC risk and severity, particularly in transplant recipients and those with autoimmune diseases or AIDS.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer.
- Merkel cell polyomavirus (MCPyV) is implicated in MCC development.
- Impaired immune responses can exacerbate MCPyV infectivity and MCC risk.
Purpose of the Study:
- To review the role of immunosuppression in MCC development.
- To describe various immunodeficient states associated with MCC.
- To summarize MCC in immunosuppressed patients, including case studies.
Main Methods:
- Literature review of data on immunosuppression and MCC.
- Analysis of case studies and series of MCC in immunosuppressed individuals.
- Identification of risk factors and clinical characteristics of MCC in immunocompromised patients.
Main Results:
- Immunosuppression, including UV radiation, organ transplantation, HIV/AIDS, autoimmune diseases, and lymphoproliferative disorders, increases MCC risk.
- Iatrogenic immunosuppression also contributes to MCC development.
- Immunocompromised patients often experience earlier onset, more aggressive MCC, and poorer outcomes.
Conclusions:
- Individuals with a history of organ transplantation, autoimmune diseases, AIDS, and lymphoproliferative diseases have a significantly higher risk of MCC.
- Multidisciplinary approaches are recommended for MCC prevention and management in immunocompromised patients.
